Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

Company Overview

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Key Stats

• Today's Range: $0.55 to $0.58
• 50-Day Range: $0.35 to $0.96
• 52-Week Range: $0.00 to $6.81
• Volume: 10,892 shs
• Average Volume: 172,541 shs
• Market Capitalization: $7.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Eagle Pharmaceuticals Stock Analysis - MarketRank™

Eagle Pharmaceuticals scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Eagle Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Eagle Pharmaceuticals has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for EGRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eagle Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eagle Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.29

Short Interest

There is no current short interest data available for EGRX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for EGRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Eagle Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EGRX Stock Analysis - Frequently Asked Questions

How have EGRX shares performed this year?

Eagle Pharmaceuticals' stock was trading at $5.23 on January 1st, 2024. Since then, EGRX stock has decreased by 89.5% and is now trading at $0.55.
View the best growth stocks for 2024 here.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to the consensus estimate of $46.70 million.

Who are Eagle Pharmaceuticals' major shareholders?

Top institutional investors of Eagle Pharmaceuticals include RBF Capital LLC (1.10%), Jacobs Levy Equity Management Inc. (0.94%), DGS Capital Management LLC (0.55%) and Jane Street Group LLC (0.20%). Insiders that own company stock include Scott Tarriff and Richard A Edlin.
View institutional ownership trends.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EGRX
• CUSIP: N/A
• CIK: 827871
• Web: www.eagleus.com
• Phone: (201) 326-5300
• Fax: N/A
• Employees: 134
• Year Founded: 2007

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $257.55 million
• Price / Sales: 0.03
• Cash Flow: $3.06 per share
• Price / Cash Flow: 0.18
• Book Value: $17.94 per share
• Price / Book: 0.03

Miscellaneous

• Outstanding Shares: 12,987,000
• Free Float: 9,234,000
• Market Cap: $7.14 million
• Optionable: Optionable
• Beta: 0.68